THE KEY TO
IMMUNOTHERAPY

The key to immunotherapy

Cytovac is a growing Danish biotech company, which has chosen to focus on development of a cancer treatment that uses the body’s own immune system.

Promising results gained by the dedicated research team over a number of years, have brought about the development of the ALECSAT therapy. ALECSAT is a therapy based on injection of activated cells from the immune system to patients. These cells will attack the cancer cells and activate the immune system. As Cytovac solely apply the patient’s own cells, this therapy is gentle and without the side effects associated with existing cancer therapies.

umano_cytovac_020-ny2

Treatment
Method

produktcirkel2

Latest News

Timeline

tidslinie_eng2

Investors

Cytovac in brief

Cytovac may provide cancer patients with effective and gentle immunotherapy treatments.

The injected cells will kill cancer cells – and there are indications that the treatments will also reactivate existing, but suppressed, immune system cells in the patient’s body; these cells may then also become active in the fight against cancer cells.

The therapy has successfully been tested in clinical phase I and phase II trials in Prostate, Pancreatic and GBM Brain cancer. There are indications of positive clinical effects for many of the patients treated.

More than 100 patients have been treated and more than 250 doses administered – without detection of the serious adverse effects associated with existing cancer therapies.

Cytovac has documented that the established production method is efficient, the product is manufactured on the basis of a blood donation from the individual patient – without use of advanced and expensive techniques – leading to a rapid and easy production procedure.

Cytovac has its own GMP production unit. The production platform can be scaled up and potentially disseminated globally.

Cytovac products may be distributed to most of Europe and are today shipped to Scandinavia and Iceland for clinical testing.

The Cytovac immunotherapy is patent protected and the brain cancer program has been granted Orphan Drug Designation by EMA and FDA.

ALECSAT is manufactured on the basis of a blood donation from the individual patient – without the use of advanced and expensive techniques – leading to a rapid and easy production procedure.
umano_cytovac_1-640x440